Our company has a history of innovation and continues to invest significantly in research and development. We believe our commitment to this suit and the decision demonstrate our resolve to protect our intellectual property.
La Vista, NE (Vocus) October 26, 2010
The United States District Court for the District of Nebraska (Case # 8:09CV410) has issued a permanent injunction, enjoining Minneapolis-based Research and Diagnostic System, Inc. (R&D) from selling three integrated hematology reticulocyte controls called CBC-XE, CBC-4K Plus Retics, and CBC-5D Plus Retics.
The Court had previously determined that these three R&D controls infringed. R&D had argued that it, not Streck, Inc., was the first to invent the patented controls, and that Streck’s patents were invalid.
The Court’s decision today also upheld the validity of Streck’s patents, finding that Streck, rather than R&D, was the first inventor of integrated reticulocyte controls. Streck is now the only U.S. manufacturer of integrated hematology reticulocyte controls, which contain a white blood cell five-part differential and a reticulocyte component in one vial.
“We are very pleased with this decision,'' commented Connie Ryan, President of Streck. ''Our company has a history of innovation and continues to invest significantly in research and development. We believe our commitment to this suit and the decision demonstrate our resolve to protect our intellectual property."
About Streck, Inc.
Streck, Inc., a privately held company with more than 320 employees, was founded in 1971 and is an industry leader in cell stabilization. Streck specializes in the development and manufacture of control and calibration materials for the clinical laboratory.
7002 South 109 Street • Omaha, NE 68128 • 800-843-0912